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A B S T R A C T
Introduction. Vaginal atrophy, which may affect up to 45% of postmenopausal women, is often associated with one
or more urinary symptoms, including urgency, increased frequency, nocturia, dysuria, incontinence, and recurrent
urinary tract infection.
Aims. To provide an overview of the current literature regarding cellular and clinical aspects of vaginal atrophy and
response to treatment with local vaginal estrogen therapy.
Methods. PubMed searches through February 2012 were conducted using the terms “vaginal atrophy,” “atrophic
vaginitis,” and “vulvovaginal atrophy.” Expert opinion was based on review of the relevant scientiﬁc and medical
literature.
Main Outcome Measure. Genitourinary symptoms and treatment of vaginal atrophy from peer-reviewed published
literature.
Results. Typically, a diagnosis of vaginal atrophy is made based on patient-reported symptoms, including genito-
urinary symptoms, and an examination that reveals signs of the disorder; however, many women are hesitant to
report vaginal-related symptoms, primarily because of embarrassment.
Conclusions. Physicians in various disciplines are encouraged to initiate open discussions about vulvovaginal health
with postmenopausal women, including recommended treatment options. Goldstein I, Dicks B, Kim NN, and
Hartzell R. Multidisciplinary overview of vaginal atrophy and associated genitourinary symptoms in post-
menopausal women. Sex Med 2013;1:44–53.
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Introduction
Vaginal atrophy is a common disorder in post-menopausal women that often occurs with
urinary symptoms and causes considerable distress
[1–3]. Typically, women with vaginal atrophy
experience dryness, itching, irritation, burning,
and dyspareunia. They also commonly present
with one or more urinary symptoms, including
urgency, increased frequency, nocturia, dysuria,
incontinence, and recurrent urinary tract infec-
tion (RUTI). When any of these symptoms are
left untreated, they may contribute to a lower
quality of life marked by vaginal discomfort, pain,
and sexual dysfunction [1–3].
Nonsexual and urologic aspects of vaginal
atrophy have a signiﬁcant psychosocial effect sepa-
rate from that of dyspareunia, which has been dis-
cussed elsewhere [4,5]. RUTI interrupts daily
functioning and reduces libido, which may nega-
tively affect personal relationships and psychoso-
cial health. Additionally, sex is more unpleasant
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with urinary urgency and the possibility of incon-
tinence because women may experience fear of
odor, embarrassment, shame, and loss of self-
esteem [6]. Meanwhile, sleep loss from nocturia
affects mood and social interactions, which may
further affect personal well-being and relation-
ships. Bothersome vulvovaginal symptoms may
cause signiﬁcant personal distress, while related
sexual dysfunction may affect a woman’s ego and
life satisfaction [7]. Symptoms of vaginal atrophy
may also remind women that they are aging, and
the perception that their bodies are no longer
responding or acting as they used to may create
anxiety and depression. Furthermore, loss of elas-
ticity to vulvovaginal tissues, thinning of the
vaginal wall, and decreased vaginal lubrication may
increase the risk for microtears or genital lesions
during intercourse, which could allow easier trans-
mission of sexually transmitted infections.
The burden of vaginal atrophy on the individual
and on the population is greater than most
physicians realize. Up to 45% of postmenopausal
women experience symptoms of vaginal atrophy
[8,9]. In the recent Vaginal Health: Insights, Views
& Attitudes (VIVA) international survey of 3,520
women, the 45% of postmenopausal women who
reported vaginal discomfort experienced a range of
symptoms, including dryness (83%), dyspareunia
(42%), involuntary urination (30%), soreness
(27%), itching (26%), burning (14%), and pain
(11%) [9]. Despite the high prevalence of such
symptoms, only about 25% of affected women
seek medical assistance [1]; reasons for not seek-
ing medical help include embarrassment and the
belief that their symptoms are an inevitable part
of aging [4,8].
Aims
This article aims to provide an overview of the
urogenital changes of menopause, the cellular
effect of estrogen and its deﬁciency, the effect of
local estrogen therapy on women with urogenital
symptoms, the clinical management of vaginal
atrophy, and the role various health care profes-
sionals (primary care physician, gynecologist,
urologist, and sex therapist) can have in recogniz-
ing vaginal atrophy as a cause of urinary com-
plaints in postmenopausal women.
Methods
Peer-reviewedpublicationswere identiﬁed through
a PubMed search using the search terms “vaginal
atrophy,” “atrophic vaginitis,” and “vulvovaginal
atrophy.” The search was completed through Feb-
ruary 2012 and was limited to articles published
in English. Relevant articles were identiﬁed based
upon the expertise and clinical experience of
the authors.
Main Outcome Measures
The main outcome measures for this study were
genitourinary symptoms and treatment of vaginal
atrophy from peer-reviewed published literature.
Results
Urogenital Changes of Menopause
Upon menopause, a decrease in estrogen produc-
tion by the ovaries affects several of the urogenital
tissues, including the vagina, urethra, bladder
trigone, and pelvic ﬂoor musculature, all of which
contain estrogen receptors (ERs) [2]. In the vagina,
estrogen maintains the thickness of the muscularis
and squamous vaginal epithelium, which is nor-
mally characterized by rugae, moisture and a pink
color [2]. Estrogen also stimulates vaginal epithelial
cells to produce glycogen. As these epithelial cells
are shed into the vaginal lumen, glycogen is hydro-
lyzed to glucose and metabolized by native ﬂora
(lactobacilli) into lactic acid, which maintains
vaginal pH at approximately 3.5–4.5 [2].
After themenopausal transition, the ovary ceases
to synthesize estrogen. The subsequent decline in
circulating estrogen results in fewer vaginal epithe-
lial cells and reduced glycogen content per cell. As
the main nutritional substrate of microbial ﬂora in
the vagina, decreased glycogen results in lower
production of acidic metabolites (e.g., lactic acid)
and a higher pH in the vaginal lumen. This alkaline
milieu further hinders the survival of lactobacilli
and permits the overgrowth of other species,
including streptococci, staphylococci, coliforms,
and diphtheroids. Reduced vaginal estradiol there-
fore results in an altered microbial environment
and predisposes postmenopausal women to vaginal
infections and/or RUTIs. Before menopause,
reproductive cycling of 17β-estradiol also supports
the elasticity of the tissues surrounding the
urogenital tract by inhibiting proliferation of con-
nective tissue, fragmentation of elastin, and
hyalinization of collagen. After menopause, the
reduction in 17β-estradiol leads to a loss of elastic-
ity in the vulvovaginal tissues [2].
Estrogen deﬁciency is one of many factors,
including age, which can inﬂuence the develop-
ment of urinary symptoms, such as urgency,
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increased frequency, incontinence, andUTI [2,10].
Predisposing factors for lower urinary tract symp-
toms include history of UTI, vaginal colonization
withEscherichia coli, diabetic peripheral neuropathy,
hysterectomy, obesity, chronic constipation, and
general chronic illness [11]. The effects of estro-
gen on particular urinary tract symptoms will be
reviewed later in this article.
Cellular Effects of Decreased Estrogen
Although estrogen is a major regulator of vaginal
epithelial growth, vaginal atrophy is not limited
to being a vaginal mucosal condition, as sug-
gested in the previous section. The vagina con-
sists of three tissue layers: the muscularis, the
lamina propria, and the vaginal epithelium. All
three vaginal wall layers have ERs and are
responsive to sex steroid hormones [12]. As dis-
cussed in the following paragraphs, ERs are
present throughout the lower urinary tract and
can regulate bladder smooth muscle contractility,
as well as vaginal tissue perfusion, cellular and
extracellular composition, overall structure and
nerve density [13,14].
Aside from vaginal epithelial health, however,
the mechanisms of action of estrogen in the female
genitourinary tissues and the clinical effectiveness
of estrogen supplementation in vaginal atrophy
have been poorly characterized. The clearest evi-
dence to suggest that estrogen regulates the
growth and function of vascular and nonvascular
smooth muscle in the subepithelial layers of the
vagina, the lamina propria, and the muscularis,
affecting vaginal wall perfusion and vaginal wall
smooth muscle tone, is found in laboratory animal
studies [13,14].
In an animal model of estrogen deﬁciency
(ovariectomized rats), autonomic nerve density
within the vagina also increased, even after nor-
malizing for tissue atrophy [15]. Overall, the
density of nerve ﬁbers increases in estrogen-
deﬁcient animals, mostly because of an increase
in sympathetic adrenergic, parasympathetic
cholinergic, and sensory nociceptor nerves [15].
Systemic estrogen replacement reduces vaginal
nerve density to a level comparable to that found
in intact and normally cycling rats [15]. Because
a major contributor to vaginal moisture is
plasma transudate derived from the subepithelial
vasculature, increased sympathetic innervation
may cause vasoconstriction, leading to vaginal
dryness and vaginal wall hypertonus. Further-
more, a greater density of sensory nociceptors
may contribute to hypersensitivity and result in
symptoms of pain, burning, and itching.
Expression of the ER is also regulated by native
17β-estradiol in the vagina. Estrogen-deﬁcient
animals express higher amounts of functional ER
protein (speciﬁcally the ERα subtype) throughout
the three layers of the vaginal wall, and a greater
proportion of the receptor is found in the nuclear
compartment, presumably as activated receptor
[14,16]. This may serve as a homeostatic mecha-
nism to buffer against changes in estrogen levels
that may occur during the normal premenopausal
ovarian cycle. Severe estrogen deﬁciency, as occurs
in postmenopausal women, overcomes this protec-
tive mechanism and results in tissue atrophy.
In human vaginal tissue, ERα messenger RNA
(mRNA), which may be used to estimate expres-
sion of the ERα protein, increases in postmeno-
pausal women who are not receiving hormone
therapy, whereas ERα mRNA in women using sys-
temic hormone replacement therapy decreases to
levels similar to those found in premenopausal
women [17]. Postmenopausal women prescribed
local estrogen therapy maintain elevated levels of
vaginal ERα mRNA, presumably because of the
absorption of lower levels of estrogen [17]. There-
fore, it is not unreasonable to conclude that ERα
regulation in humans may be similar to that in
laboratory animal models of estrogen deﬁciency.
The reciprocal regulation between circulating
estrogen levels and ERα expression may serve as a
rationale for using low doses of estrogen in the
vagina in postmenopausal women to maximize the
effects of local estrogen treatment.
Although expression of ERβ in the vagina has
been documented, its role remains unclear.
Upregulation of ERβ in women has been associ-
ated with various states of disease, including stress
urinary incontinence [18] and vulval lichen
sclerosus [19], although ERβ also mediates critical
processes in normal tissue function and is impor-
tant for maintaining health. Low ERβ expression
in the vaginal tissue has been associated with
genital prolapse in postmenopausal women [20],
and a complete deﬁciency of ERβ leads to the
onset of ulceration and atrophy in the bladder
urothelium of female mice that lack the ERβ gene
[21]. The complexity of ERβ signaling remains to
be fully elucidated and is likely based on the inter-
play between multiple isoforms, most of which are
not functional receptors but modiﬁers of receptor
activity [22].
In addition to direct trophic effects on urogeni-
tal tissues, the association of estrogen withdrawal
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with increased urinary symptoms results from
multiple additional factors. In laboratory studies,
estradiol suppresses contraction of the rat detrusor
smooth muscle, decreasing spasmodic activity [23],
and inhibits the expression of rho-kinase, a key
regulator of smooth muscle contraction in urethral
smooth muscle cells [24]. Thus, estrogen deﬁ-
ciency can lead to increased contractility of
bladder and urethral smooth muscle. Additionally,
in healthy women, collagen turnover in urogenital
tissue has been shown to increase in response to
estradiol treatment [25], which suggests that estro-
gen deﬁciency may disrupt normal connective
tissue metabolism. It should be emphasized that
ERs were not detected in the striated muscle of the
pelvic ﬂoor in women [26], suggesting that these
voluntary muscles are not directly involved in the
etiology of urinary symptoms caused by estrogen
deﬁciency.
Estrogen is an important regulator of tissue
growth and function in the lower urinary tract;
however, testosterone plays an important role as
well. Like ERs, the androgen receptor (AR) is
expressed throughout the vaginal wall, the bladder,
and the urethra [16,27]. Testosterone, indepen-
dent of estradiol, has been shown to modulate
vaginal wall contractility and perfusion and to
upregulate AR in rats [13,16,28]. In addition, AR is
localized to motoneurons innervating the urethral
sphincter and the pubococcygeus muscle [29,30],
suggesting that testosterone supplementation
regimens may be somewhat effective in ameliorat-
ing urinary symptoms and urogenital tissue
atrophy [31,32]. Because of the importance of
estrogen and testosterone in maintaining vaginal
health, intravaginal dehydroepiandrosterone, a
precursor sex steroid that is converted directly to
various androgens and eventually converted to
estradiol in the vaginal epithelium and muscularis
[10,33], is under investigation as an alternative to
local estradiol therapy [34].
Clinical Effects of Local Estrogen Therapy for
Vaginal Atrophy
On the tissue/organ level, exogenous estrogen
increases blood ﬂow, epithelial thickness, and
secretions while decreasing pH [1]. These changes
are reﬂected in positive clinical signs, including
less vulvovaginal pallor and increased moisture.
Moreover, patients receiving local vaginal estro-
gen therapy generally report less itching and irri-
tation and reduced dyspareunia [35]. From a
psychosocial perspective, a number of women
using local estrogen therapy reported positive
effects, including normalization of sex life, better
quality of life, improvement in their relationship
with their partner, feeling “less old,” higher self-
esteem, and a better social life [8].
Generally, local vaginal estrogen products
approved for the treatment of vaginal atrophy in
the United States are not indicated for the treat-
ment of RUTI, although urinary symptoms often
improve after estrogen is restored to the vagina
[11]. Signiﬁcant evidence suggests a positive effect
of local vaginal estrogen therapy on RUTI;
however, the data supporting oral estrogen
therapy are less convincing [36]. Some evidence
supports the improvement of overactive bladder
and urgency incontinence as a result of local
vaginal estrogen therapy. Frequency, urgency,
and/or number of incontinent episodes may
improve [37], but recent analysis suggests that
local treatment rather than systemic treatment
is important [38]. Urodynamic parameters, such
as number of uninhibited detrusor contrac-
tions and maximal cystometric capacity, may also
improve [39].
Clinical Management of Vaginal Atrophy
Typically, a diagnosis of vaginal atrophy is made
based on patient-reported symptoms and an
examination that reveals signs of the disorder
(Table 1; Figure 1). The diagnosis may be
Table 1 Common patient-reported symptoms and clinical signs of vaginal atrophy
Vulvovaginal symptoms Urinary symptoms Clinical signs
• Dryness
• Itching
• Irritation
• Burning
• Dyspareunia
• Urgency
• Increased frequency
• Nocturia
• Dysuria
• Incontinence
• RUTI
• Pale, dry vulvar and vaginal mucosae
• Reduction in volume of the labia
• Scarcity of pubic hair
• Shortened and narrowed vagina
• Reduced or nonexistent rugae
• Erythema indicative of inflammation
• Petechiae
• Psychosocial signs (e.g., decreased quality of life)
RUTI = recurrent urinary tract infection
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conﬁrmed by vaginal pH test or vaginal maturation
index assessment.
First- and Second-Line Treatments
Vaginal atrophy may ﬁrst be treated by over-the-
counter vaginal moisturizers and lubricants. Sexual
activity is also recommended, but only if it is com-
fortable. Some women are advised that continued
sexual activity is important, but they are not told
that sex should not be painful or uncomfortable.
Continuing to engage in sexual activity when it
causes signiﬁcant pain or bother can result in local
tissue damage and contribute to further sexual
dysfunction. The North American Menopause
Society (NAMS) recognizes that ﬁrst-line treat-
ments (moisturizers, lubricants, and continued
sexual activity) are inadequate for some women,
particularly those with moderate-to-severe vaginal
atrophy [3]. For these cases, NAMS recommends
low-dose, local vaginal estrogen therapy, which
is effective and well tolerated (Table 2 [40–43]).
NAMS recommends that clinical experience
and patient preference determine the choice of
therapy [3].
Recently, a new oral treatment was approved in
the United States. Ospemifene is an estrogen
agonist/antagonist approved for the treatment of
moderate to severe dyspareunia, a symptom of
vulvar and vaginal atrophy due to menopause [44].
Formulations of Local Vaginal Estrogen
Four local vaginal estrogen products are approved
in the United States for the treatment of vaginal
atrophy: the conjugated estrogens cream [45], and
an estradiol cream [46], vaginal ring [47], and
vaginal tablet [48]. While vaginal estrogen prepa-
rations have been available for decades, the recent
trend has been to use ultralow doses because this
minimizes systemic exposure and associated risks.
For example, the estradiol ring, containing a res-
ervoir of 2 mg estradiol, releases approximately
7.5 mcg of estradiol per day [47], while the recom-
mended estradiol vaginal tablet regimen provides
even less, with only 10 mcg of estradiol twice a
week after the initial 2-week phase of daily dosing
has passed [48], and has been shown to have the
lowest maximum annual delivered dose of the
local vaginal estrogen products [49]. Notably, the
10-mcg estradiol vaginal tablet maintains systemic
estradiol concentrations in the normal postmeno-
pausal range [50]. The conjugated estrogens cream
is also effective at a low dose: 0.5 g cream (equiva-
lent to 0.3 mg conjugated estrogens) twice a week
[40]. Lack of endometrial proliferation in response
to low-dose vaginal estrogen treatment [40,42,43]
obviates the need for coadministration of proges-
terone in women with an intact uterus.
A 2006 Cochrane review compared the efﬁcacy
of intravaginal estrogenic creams, pessaries, tablets,
and rings with one another and with placebo
in relieving the symptoms of vaginal atrophy, as
well as the safety of each product. Overall, all
intravaginal preparations appeared to be effective
for the treatment of vaginal atrophy. However, one
trial showed signiﬁcant adverse effects associated
with use of the conjugated equine estrogen cream
when compared with estradiol tablets; these
adverse events included uterine bleeding, breast
pain, and perineal pain [35].
Recommendations for Breast Cancer Survivors
In patients with a history of hormone-dependent
cancer, an oncologist should be consulted before
hormonal treatment. Results of observational
studies of use of topical vaginal estrogen in
patients with a history of hormone-sensitive breast
cancer have been favorable, but the lack of a large
randomized trial prevents the making of general
Figure 1 Atrophy of the vulva, clitoris, and vagina. (A)
Vaginal atrophy is associated with pale, dry, shiny vulvar
tissue and loss of adipose tissue in the labia majora and
labia minora. (B) The prepuce and clitoris are often pale and
reduced in size, while examination shows that (C) the
introitus may be narrowed and friable. (D) In vaginal
atrophy, the vaginal walls lack rugae and may be pale
and/or erythematous.
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recommendations [51]. Although some patients
may be comfortable with taking low doses of
vaginal estrogen to manage severe vaginal atrophy,
others may prefer to use nonhormonal methods
[52,53]. Patients with a history of nonhormone-
dependent cancer may be treated similarly to
patients with no history of cancer.
The Role of Health Care Professionals
Generally, women are hesitant to report vaginal-
related symptoms, primarily because of em-
barrassment [8]. The recent “women’s voices
in the menopause” survey [8] of 4,246 women
55–65 years of age found that only 30% of women
with vaginal discomfort had spoken to a gynecolo-
gist about their symptoms and only 29% had
spoken with a general practitioner. Strikingly, 30%
of women with vaginal discomfort had not spoken
to anyone about it, for reasons including, “I do
not think other people want to hear about my
vaginal problems,” “It makes me uncomfortable/
embarrassed,” “It is private and does not concern
others,” and “It’s just part of growing older” [8].
Nearly one-third (31%) of women with vaginal
discomfort expressed the preference that a physi-
cian initiate a discussion on the topic [8], which
suggests that a similar percentage of women might
be receptive to discussing vaginal discomfort and
potential treatment options with their health care
professional.
Primary Care Physician
In the VIVA study, 50% of women identiﬁed
their primary care doctor as a source they had or
would use for information on vulvovaginal symp-
toms and/or treatment options [9]. In the Preva-
lence of Female Sexual Problems Associated with
Distress and Determinants of Treatment Seeking
study, women ≥65 years were more likely to
speak to their primary care physician (54%) than
their gynecologist (30%) about their sexual prob-
lems [54]. Because many women are hesitant to
report symptoms without prompting [8], primary
care physicians are encouraged to ask postmeno-
pausal women about any discomfort or lower
urinary tract symptoms, including a history of
RUTIs [55].
Gynecologist
Gynecologists play an important role in identify-
ing vaginal atrophy in postmenopausal women.
Routine gynecological exams may help identify
symptoms of and diagnose vaginal atrophy. In the
VIVA study, 46% of women identiﬁed their gyne-
cologist as a source they had used or would use to
understand vulvovaginal symptoms and/or treat-
ment options [9]. As many women start experienc-
ing perimenopausal symptoms around age 40, this
may be a good time for gynecologists to begin
conversations with women about changes in sexual
health [56]. It has been recommended that gyne-
cologists add questions about vulvovaginal and
urinary symptoms to intake paperwork, directly
question patients on symptoms, and reﬂexively
question the patient on vulvovaginal and urin-
ary symptoms based on ﬁndings of the physical
exam [55].
Urologist
The urologist is in the unique position of being
able to provide this advice because women may not
feel comfortable visiting a physician for vaginal
symptoms alone. The urologist should consider
vaginal atrophy as a potential cause of urinary
symptoms in a postmenopausal woman. Increased
awareness that vaginal atrophy may be the under-
lying cause of urological symptoms is important
for facilitation of proper diagnosis and treatment.
Vaginal atrophy is a chronic condition; therefore,
the urologist may wish to refer a patient with
vaginal atrophy to a gynecologist for long-term
management. In most moderate-to-severe cases of
vaginal atrophy, prescribing local vaginal estrogen
is the quickest and most effective way to relieve
symptoms. After as few as 2 weeks of therapy [41],
positive urogenital changes may be evident. The
urologist may also provide several practical tips to
menopausal women with vaginal atrophy. These
include regular use of moisturizers; use of lubri-
cants for sexual activity; avoidance of the use of any
product near the vulva that may exacerbate symp-
toms, including scented soaps, lotions, or panty
liners; regular sexual activity, as soon as it becomes
manageable without pain or discomfort; and sex
therapy, as described in the next section, to
develop and implement strategies to increase
sexual satisfaction and quality of life.
Sex Therapists
The nonphysical ramiﬁcations of pain, discomfort,
and vaginal dryness during sexual activity may be
addressed through sex therapy, a specialized form
of counseling or psychotherapy designed to help
individuals and couples with sexual problems [57].
Women may experience a variety of emotions as a
result of vaginal atrophy, and a therapist can offer
support to women struggling with urogenital
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discomfort, incontinence, aging, body image con-
cerns, or low self-esteem. In couples therapy, a
therapist can help the woman and her partner
communicate about the changes to her body and
how these changes can affect their relationship.
The therapist can assist the couple in exploring a
variety of sexual activities that may be less irritat-
ing to the vagina, such as oral sex, manual stimu-
lation, sensual touch, and the use of vibrators. The
therapist can also provide education regarding dif-
ferent types of lubricants (e.g., water based and
silicone based) and help the couple ﬁnd one that is
enjoyable and does not irritate the vaginal tissue.
The key to helping couples with vaginal atrophy is
to devise manageable behavioral changes that will
help them rediscover a satisfying sex life.
Women may not be aware that there is help for
the nonphysical effects of vaginal atrophy, or they
may be too embarrassed to ask for it. Health care
professionals might consider directly asking their
patients about the impact of vaginal symptoms on
their patients’ sexual relationships and offer refer-
rals to interested patients.
Conclusions
Vaginal atrophy is a common condition that is
under-recognized and undertreated, primarily
because physicians and patients typically do not
include vulvovaginal health issues in their discus-
sions. For health care professionals, the challenge
is to identify female patients whose urinary symp-
toms may be related to concurrent vaginal atrophy.
The ﬁrst step in making a difference in the quality
of life for these women is for health care profes-
sionals to be aware that certain urinary complaints
may be reﬂective of postmenopausal estrogen deﬁ-
ciency. Primary care physicians are encouraged to
ask postmenopausal women about any discomfort
or lower urinary tract symptoms, including a
history of RUTIs, and gynecologists are encour-
aged to add questions about vulvovaginal and
urinary symptoms to intake paperwork. The key to
improved outcomes for menopausal women is the
guidance of physicians who inquire about their
nonurinary symptoms, such as vaginal dryness,
itching, and dyspareunia, encourage open discus-
sions about vulvovaginal health and recommended
treatment options, including local vaginal estrogen
therapy. Referral to sex therapists may help
address the impact of vaginal atrophy on a
woman’s personal relationships and psychosocial
health.
Acknowledgments
Editorial assistance was provided by Pamela Barendt,
PhD, ETHOS Health Communications, Newtown,
Pennsylvania, with ﬁnancial assistance from Novo
Nordisk, Inc, Princeton, New Jersey, in compliance
with international guidelines on good publication prac-
tice. The authors received no remuneration of any kind
for the development of this manuscript.
Corresponding Author: Irwin Goldstein, MD, San
Diego Sexual Medicine, 5555 Reservoir Drive, Suite
300, San Diego, CA 92120, USA. Tel: (619) 265-8865;
Fax: (619) 265-7696; E-mail: dr.irwingoldstein@gmail
.com
Conﬂict of Interest: Brian Dicks has nothing to disclose.
Rose Hartzell has received research support from Emo-
tional Brain, Palatin, and Trimel. Noel N. Kim is a
consultant for Alagin Research LLC and Absorption
Pharmaceuticals, and has received research funding from
Pﬁzer and Astellas. Irwin Goldstein has received
research support from Absorption Pharmaceuticals,
Auxilium, BioSante, Emotional Brain, Endoceutics,
Medtronic, Neogyn, Palatin, Repros, Slate, Target
Health, and Trimel. He is a consultant for Apricus,
Emotional Brain, Fabre-Kramer, Ironwood, Meda,
Medtronic, Neogyn, Neotract, Slate, and Trimel, and
he is on the Speakers Bureau for Abbott, Auxilium,
Coloplast, Eli Lilly, Endo, and Slate.
References
1 Ibe C, Simon JA. Vulvovaginal atrophy: Current and future
therapies (CME). J Sex Med 2010;7:1042–50.
2 Sturdee DW, Panay N, on behalf of the International Meno-
pause Society Writing Group. Recommendations for the man-
agement of postmenopausal vaginal atrophy. Climacteric
2010;13:509–22.
3 The North American Menopause Society. The role of local
vaginal estrogen for treatment of vaginal atrophy in postmeno-
pausal women: 2007 position statement of The North Ameri-
can Menopause Society. Menopause 2007;14:357–69.
4 Goldstein I. Recognizing and treating urogenital atrophy in
postmenopausal women. J Womens Health (Larchmt)
2010;19:425–32.
5 Krychman ML. Vaginal estrogens for the treatment of
dyspareunia. J Sex Med 2011;8:666–74.
6 Jha S, Ammenbal M, Metwally M. Impact of incontinence
surgery on sexual function: A systematic review and meta-
analysis. J Sex Med 2012;9:34–43.
7 Goldstein I, Alexander JL. Practical aspects in the manage-
ment of vaginal atrophy and sexual dysfunction in
perimenopausal and postmenopausal women. J Sex Med
2005;2(3 suppl):154–65.
8 Nappi RE, Kokot-Kierepa M. Women’s voices in the meno-
pause: Results from an international survey on vaginal atrophy.
Maturitas 2010;67:233–8.
9 Nappi RE, Kokot-Kierepa M. Vaginal health: Insights, views
& attitudes (VIVA)—Results from an international survey. Cli-
macteric 2012;15:36–44.
10 Labrie F. DHEA, important source of sex steroids in men and
even more in women. Prog Brain Res 2010;182:97–148.
Multidisciplinary Overview of Vaginal Atrophy 51
Sex Med 2013;1:44–53© 2013 The Authors. Sexual Medicine published by Wiley Periodicals, Inc.
on behalf of International Society for Sexual Medicine.
11 Ewies AA, Alfhaily F. Topical vaginal estrogen therapy in man-
aging postmenopausal urinary symptoms: A reality or a
gimmick? Climacteric 2010;13:405–18.
12 Pessina MA, Hoyt RF, Jr, Goldstein I, Traish AM. Differential
effects of estradiol, progesterone, and testosterone on vaginal
structural integrity. Endocrinology 2006;147:61–9.
13 KimNN,Min K, Pessina MA,Munarriz R, Goldstein I, Traish
AM. Effects of ovariectomy and steroid hormones on vaginal
smooth muscle contractility. Int J Impot Res 2004;16:43–
50.
14 Kim SW, Kim NN, Jeong SJ, Munarriz R, Goldstein I, Traish
AM. Modulation of rat vaginal blood ﬂow and estrogen recep-
tor by estradiol. J Urol 2004;172:1538–43.
15 Ting AY, Blacklock AD, Smith PG. Estrogen regulates vaginal
sensory and autonomic nerve density in the rat. Biol Reprod
2004;71:1397–404.
16 Pessina MA, Hoyt RF, Jr, Goldstein I, Traish AM. Differential
regulation of the expression of estrogen, progesterone, and
androgen receptors by sex steroid hormones in the vagina:
Immunohistochemical studies. J Sex Med 2006;3:804–14.
17 Skala CE, Petry IB, Albrich SB, Puhl A, Naumann G, Koelbl
H. The effect of hormonal status on the expression of estrogen
and progesterone receptor in vaginal wall and periurethral
tissue in urogynecological patients. Eur J Obstet Gynecol
Reprod Biol 2010;153:99–103.
18 Soderberg MW, Johansson B, Masironi B, Bystrom B,
Falconer C, Sahlin L, Ordeberg GE. Pelvic ﬂoor sex steroid
hormone receptors, distribution and expression in pre- and
postmenopausal stress urinary incontinent women. Acta
Obstet Gynecol Scand 2007;86:1377–84.
19 Taylor AH, Guzail M, Al-Azzawi F. Differential expression of
oestrogen receptor isoforms and androgen receptor in the
normal vulva and vagina compared with vulval lichen sclerosus
and chronic vaginitis. Br J Dermatol 2008;158:319–28.
20 Skala CE, Petry IB, Albrich S, Puhl A, Naumann G, Koelbl H.
The effect of genital and lower urinary tract symptoms on
steroid receptor expression in women with genital prolapse. Int
Urogynecol J 2011;22:705–12.
21 Imamov O, Yakimchuk K, Morani A, Schwend T,
Wada-Hiraike O, Razumov S, Warner M, Gustafsson JA.
Estrogen receptor β-deﬁcient female mice develop a bladder
phenotype resembling human interstitial cystitis. Proc Natl
Acad Sci U S A 2007;104:9806–9.
22 Leung YK, Mak P, Hassan S, Ho SM. Estrogen receptor
(ER)-β isoforms: A key to understanding ER-β signaling. Proc
Natl Acad Sci U S A 2006;103:13162–7.
23 Valeri A, Brain KL, Young JS, Sgaragli G, Pessina F. Effects of
17β-oestradiol on rat detrusor smooth muscle contractility.
Exp Physiol 2009;94:834–46.
24 Ning N, Lin G, Lue TF, Lin CS. Effects of estrogen,
raloxifene, and levormeloxifene on the expression of Rho-
kinase signaling molecules in urethral smooth muscle cells.
Urology 2010;76:1517.e1516–1511.
25 Edwall L, Carlstrom K, Jonasson AF. Different estrogen
sensitivity of urogenital tissue from women with and without
stress urinary incontinence. Neurourol Urodyn 2009;28:516–
20.
26 Bernstein IT. The pelvic ﬂoor muscles: Muscle thickness in
healthy and urinary-incontinent women measured by perineal
ultrasonography with reference to the effect of pelvic ﬂoor
training. Estrogen receptor studies. Neurourol Urodyn
1997;16:237–75.
27 Sajjad Y, Quenby S, Nickson P, Lewis-Jones DI, Vince G.
Immunohistochemical localization of androgen receptors
in the urogenital tracts of human embryos. Reproduction
2004;128:331–9.
28 Traish AM, Kim SW, Stankovic M, Goldstein I, Kim NN.
Testosterone increases blood ﬂow and expression of androgen
and estrogen receptors in the rat vagina. J Sex Med
2007;4:609–19.
29 Blanchet P, Yaici el D, Cayzergues L, Giuliano F, Jardin A,
Benoit G, Droupy S. Identiﬁcation of androgen receptors in
the motoneurons of the external urethral sphincter in the
spinal cord of female rats. Eur Urol 2005;47:118–24.
30 Cayzergues L, Yaici el D, Tabard SB, Jestin A, Blanchard P,
Giuliano F, Bensadoun H, Jardin A, Benoit G, Droupy S.
Morphological study of the spinal motoneurons controlling
the urethral sphincter of female rats: Role of androgens in a
menopausal model. J Urol 2005;173:1022–6.
31 Mammadov R, Simsir A, Tuglu I, Evren V, Gurer E, Ozyurt C.
The effect of testosterone treatment on urodynamic ﬁndings
andhistopathomorphology of pelvic ﬂoormuscles in female rats
with experimentally induced stress urinary incontinence. Int
Urol Nephrol 2011;43:1003–8.
32 Witherby S, Johnson J, Demers L, Mount S, Littenberg B,
Maclean CD, Wood M, Muss H. Topical testosterone for
breast cancer patients with vaginal atrophy related to
aromatase inhibitors: A phase I/II study. Oncologist
2011;16:424–31.
33 Labrie F, Luu-The V, Labrie C, Simard J. DHEA and its
transformation into androgens and estrogens in peripheral
target tissues: Intracrinology. Front Neuroendocrinol
2001;22:185–212.
34 Labrie F, Archer D, Bouchard C, Fortier M, Cusan L, Gomez
JL, Girard G, Baron M, Ayotte N, Moreau M, Dube R, Cote
I, Labrie C, Lavoie L, Berger L, Gilbert L, Martel C, Balser J.
Intravaginal dehydroepiandrosterone (Prasterone), a physi-
ological and highly efﬁcient treatment of vaginal atrophy.
Menopause 2009;16:907–22.
35 Suckling J, Lethaby A, Kennedy R. Local oestrogen for vaginal
atrophy in postmenopausal women. Cochrane Database Syst
Rev 2006;(4):CD001500.
36 Perrotta C, Aznar M, Mejia R, Albert X, Ng CW. Oestrogens
for preventing recurrent urinary tract infection in postmeno-
pausal women. Obstet Gynecol 2008;112:689–90.
37 Cardozo L, Lose G, McClish D, Versi E. A systematic
review of the effects of estrogens for symptoms suggestive of
overactive bladder. Acta Obstet Gynecol Scand 2004;83:892–
7.
38 Cody JD, Richardson K, Moehrer B, Hextall A, Glazener CM.
Oestrogen therapy for urinary incontinence in post-
menopausal women. Cochrane Database Syst Rev 2009;
(4):CD001405.
39 Simunic V, Banovic I, Ciglar S, Jeren L, Pavicic Baldani D,
SpremM. Local estrogen treatment in patients with urogenital
symptoms. Int J Gynaecol Obstet 2003;82:187–97.
40 Bachmann G, Bouchard C, Hoppe D, Ranganath R, Altomare
C, Vieweg A, Graepel J, Helzner E. Efﬁcacy and safety of
low-dose regimens of conjugated estrogens cream adminis-
tered vaginally. Menopause 2009;16:719–27.
41 Simon J, Nachtigall L, Gut R, Lang E, Archer DF, Utian W.
Effective treatment of vaginal atrophy with an ultra-low-dose
estradiol vaginal tablet. Obstet Gynecol 2008;112:1053–
60.
42 Simon J, Nachtigall L, Ulrich LG, Eugster-HausmannM, Gut
R. Endometrial safety of ultra-low-dose estradiol vaginal
tablets. Obstet Gynecol 2010;116:876–83.
43 Weisberg E, Ayton R, Darling G, Farrell E, Murkies A,
O’Neill S, Kirkegard Y, Fraser IS. Endometrial and vaginal
effects of low-dose estradiol delivered by vaginal ring or
vaginal tablet. Climacteric 2005;8:83–92.
44 Osphena (ospemifene) [prescribing information]. Florham
Park, NJ: Shionogi Inc.; Febraury 2013.
45 Premarin (conjugated estrogens) vaginal cream [prescribing
information]. Philadelphia, PA: Wyeth Pharmaceuticals Inc,
part of Pﬁzer; May 2010.
52 Goldstein et al.
Sex Med 2013;1:44–53 © 2013 The Authors. Sexual Medicine published by Wiley Periodicals, Inc.
on behalf of International Society for Sexual Medicine.
46 Estrace (estradiol vaginal cream, USP, 0.01%) [prescribing
information]. Rockaway, NJ: Warner Chilcott (US), LLC; July
2011.
47 Estring (estradiol vaginal ring) [prescribing information]. New
York, NY: Pharmacia & Upjohn Company, Division of Pﬁzer
Inc; Aug 2008.
48 Vagifem (estradiol vaginal tablets) [prescribing information].
Princeton, NJ: Novo Nordisk Inc; Nov 25 2009.
49 Pruthi S, Simon JA, Early AP. Current overview of the man-
agement of urogenital atrophy in women with breast cancer.
Breast J 2011;17:403–8.
50 Eugster-Hausmann M, Waitzinger J, Lehnick D. Minimized
estradiol absorption with ultra-low-dose 10 μg 17β-estradiol
vaginal tablets. Climacteric 2010;13:219–27.
51 Dew JE, Wren BG, Eden JA. A cohort study of topical vaginal
estrogen therapy in women previously treated for breast
cancer. Climacteric 2003;6:45–52.
52 Carter J, Goldfrank D, Schover LR. Simple strategies for
vaginal health promotion in cancer survivors. J Sex Med
2011;8:549–59.
53 Krychman ML, Katz A. Breast cancer and sexuality: Multi-
modal treatment options. J Sex Med 2012;9:5–13.
54 Shifren JL, Johannes CB, Monz BU, Russo PA, Bennett L,
Rosen R. Help-seeking behavior of women with self-reported
distressing sexual problems. J Womens Health (Larchmt)
2009;18:461–8.
55 Minkin M, Guess M. Diagnosis and treatment of the non–sex-
related symptoms of vulvovaginal atrophy. Female Patient
2012;37:33–41.
56 Reiter S. Barriers to effective treatment of vaginal atrophy
with local estrogen therapy. Int J Gen Med 2013;6:153–
8.
57 Althof SE. Sex therapy and combined (sex and medical)
therapy. J Sex Med 2011;8:1827–8.
Multidisciplinary Overview of Vaginal Atrophy 53
Sex Med 2013;1:44–53© 2013 The Authors. Sexual Medicine published by Wiley Periodicals, Inc.
on behalf of International Society for Sexual Medicine.
